Literature DB >> 9837760

Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance.

X Huang1, C Gottstein, R A Brekken, P E Thorpe.   

Abstract

Vascular endothelial growth factor (VEGF) is an endothelial cell specific mitogen that induces angiogenesis in several pathological conditions. To block angiogenesis, soluble VEGF receptor can be used. In this study, we describe a method for high yield expression of soluble VEGF receptor 2 (sFlk-1) in a baculovirus expression system (30 mg purified sFlk-1 per L of insect cell supernatant). We also determined the binding constants for both human and mouse VEGF to the recombinant receptor by surface plasmon resonance. In this cell-free assay, under the given experimental conditions, the on-rate ka was 0.5-2.2 x 10(6) M-1s-1 and the off-rate kd was 2-4 x 10(-4) s-1 (KD = 2-6 x 10(-10) M). To our knowledge this is the first study to report on- and off-rates for the VEGF:sFlk-1 interaction. Heparin was not required for the binding of VEGF to sFlk-1 in this assay. The obtained values will serve as baseline parameters for the design of improved versions of recombinant soluble VEGF receptor. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837760     DOI: 10.1006/bbrc.1998.9717

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Authors:  Niv Papo; Adam P Silverman; Jennifer L Lahti; Jennifer R Cochran
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

2.  Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.

Authors:  Helena Pavlakovic; Jürgen Becker; Romulo Albuquerque; Jörg Wilting; Jayakrishna Ambati
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

3.  Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.

Authors:  Sophia Ran; Xianming Huang; Amber Downes; Philip E Thorpe
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

4.  A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models.

Authors:  Yanlan Yu; Pierre Lee; Yaohuang Ke; Yongke Zhang; Qiu Yu; Jonathan Lee; Mingzhen Li; Jialiang Song; Jungang Chen; Jihong Dai; Fernando Jose Rebelo Do Couto; Zhiqiang An; Weimin Zhu; Guo-Liang Yu
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

5.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

6.  Dimerization of VEGF receptors and implications for signal transduction: a computational study.

Authors:  Feilim Mac Gabhann; Aleksander S Popel
Journal:  Biophys Chem       Date:  2007-03-24       Impact factor: 2.352

7.  Real-time monitoring biomarker expression of carcinoma cells by surface plasmon resonance biosensors.

Authors:  Chang Liu; Tingjun Lei; Kosuke Ino; Tomokazu Matsue; Nongjian Tao; Chen-Zhong Li
Journal:  Chem Commun (Camb)       Date:  2012-09-06       Impact factor: 6.222

8.  r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction.

Authors:  Laura A Sullivan; Juliet G Carbon; Christina L Roland; Jason E Toombs; Mari Nyquist-Andersen; Anita Kavlie; Kyle Schlunegger; James A Richardson; Rolf A Brekken
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

9.  Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.

Authors:  Marco Rusnati; Antonella Bugatti; Stefania Mitola; Daria Leali; Paolo Bergese; Laura E Depero; Marco Presta
Journal:  Sensors (Basel)       Date:  2009-08-20       Impact factor: 3.576

10.  Quantifying the phosphorylation timescales of receptor-ligand complexes: a Markovian matrix-analytic approach.

Authors:  M López-García; M Nowicka; C Bendtsen; G Lythe; S Ponnambalam; C Molina-París
Journal:  Open Biol       Date:  2018-09-19       Impact factor: 6.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.